2 active not recruiting, 2 completed, 2 terminated. 4 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 2, Terminated 2 |
| Phase 2 | 3 | Active not recruiting 2, Completed 1 |
Follow CDX-1127: new trials by email Literature Review of CDX-1127 trials Research Report on CDX-1127
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer Atezolizumab, Biopsy, Biospecimen Collection - Metastatic Distal Bile Duct Adenocarcinoma, Metastatic Gallbladder Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 57 | 2021-12-15 | 2025-05-23 |
| Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC Atezolizumab 1200 MG in 20 ML Injection, Stereotactic Body Radiation Therapy, Varlilumab 3 mg/kg - Refractory Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 | Phase 1 | Terminated | Rutgers, The State University of New Jersey | 16 | 2019-09-11 | 2026-02-05 |
| Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas Nivolumab, Varlilumab - ALK-Positive Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 54 | 2018-12-21 | 2026-10-26 |
| Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma 6MHP, Montanide ISA-51, polyICLC - Melanoma | Phase 1 / Phase 2 | Completed | Craig L Slingluff, Jr | 33 | 2018-11-13 | 2024-02-06 |
| A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG) IMA950, poly-ICLC, Varlilumab - Glioma, Malignant Glioma | Phase 1 | Terminated | Nicholas Butowski | 14 | 2017-04-03 | 2024-06-14 |
| A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers CDX-1127 - CD27 Expressing B-cell Malignancies for Example Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 | Completed | Celldex Therapeutics | 90 | 2011-10-01 | 2018-01-31 |
Carcinoma, Non-Small-Cell Lung (2) · Melanoma (2) · Astrocytoma (1) · Burkitt Lymphoma (1) · Carcinoma, Renal Cell (1) · Cholangiocarcinoma (1) · Gallbladder Neoplasms (1) · Glioma (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lung Neoplasms (1) · Lymphoma, B-Cell (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Follicular (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Mantle-Cell (1)
National Cancer Institute (NCI) (2) · Celldex Therapeutics (1) · Craig L Slingluff, Jr (1) · Nicholas Butowski (1) · Rutgers, The State University of New Jersey (1)
United States (6)
Craig L Slingluff, Jr., MD (1) · Hideho Okada, MD, PhD (1) · Jyoti Malhotra (1) · Nicholas Butowski, MD (1) · Nilofer S Azad (1) · Salma Jabbour (1) · Stephen M Ansell (1)
P30CA072720 (1), R21CA233856 (1), UM1CA186686 (1), UM1CA186691 (1), UM1CA186709 (1)